Meeting
2018 ASCO Annual Meeting
Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.
Authors
Nathaniel R. Evans
Thomas Jefferson University, Philadelphia, PA
Nathaniel R. Evans , Scott Cowan , Charalambos Solomides , D. Craig Hooper , Larry Harshyne , Grace L. Lu-Yao , Hushan Yang , Linda Phan , Dawn Poller , Benjamin Leiby , Maria Werner-Wasik , Bo Lu , Jennifer Maria Johnson , Rita Susan Axelrod , Athanassios Argiris , Ralph Zinner
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT03366766
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS8582)
DOI
10.1200/JCO.2018.36.15_suppl.TPS8582
Abstract #
TPS8582
Poster Bd #
187a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Neoadjuvant nivolumab (N) plus cisplatin (C)/pemetrexed (P) or cisplatin /gemcitabine (G) in resectable NSCLC.
First Author: Ralph Zinner
Poster
2017 ASCO Annual Meeting
A phase III trial to compare atezolizumab (atezo) vs best supportive care (BSC) following adjuvant chemotherapy in patients (pts) with completely resected NSCLC: IMpower010.
First Author: Heather A. Wakelee
Poster
2014 ASCO Annual Meeting
A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).
First Author: David Paul Carbone
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre